{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T12:03:56Z","timestamp":1792325036510,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Some patients with neuromyelitis optica spectrum disorder (NMOSD)-like symptoms test negative for anti-aquaporin-4 (anti-AQP4) antibodies. Among them, a subset has antibodies targeting myelin oligodendrocyte glycoprotein (MOG), a condition now termed MOG antibody-associated disease (MOGAD). MOGAD shares features with NMOSD, like optic neuritis and myelitis, but differs in pathophysiology, clinical presentation, imaging findings, and biomarkers. The present study investigated the prevalence of anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibodies in anti-AQP4 seronegative Egyptian patients initially diagnosed with NMOSD and the link between their presence and clinical characteristics and disease-induced disability to gain insights into MOGAD. This pilot cross-sectional study included 40 anti-AQP4 antibody-negative patients initially diagnosed with NMOSD, six children and 34 adults. They were screened for anti-MOG antibodies by the indirect immunofluorescence cell-based assay. Of all included patients, only 7.5% (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093) were positive for anti-MOG antibodies and had significantly higher disability scores than seronegative patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021). The presence of anti-MOG antibodies was not significantly associated with age (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.696), gender (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.232), type of relapse (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.488), number of attacks (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.968), family history of consanguinity (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.211), family history of autoimmune disease (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.608), nor with smoking (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.608). Detecting anti-MOG antibodies in anti-AQP4-negative NMOSD patients is essential for accurate diagnosis and personalized treatment, as MOGAD is now recognized as a separate clinical entity.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-83760-2","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:09:57Z","timestamp":1736395797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical characteristics of anti-myelin oligodendrocyte glycoprotein antibody among aquaporin-4 negative neuromyelitis optica spectrum disorders in Egyptian patients"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-8701","authenticated-orcid":false,"given":"Sara I.","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa I.","family":"Bakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermeen T.","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Zamzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"83760_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jneuroim.2018.08.014","volume":"324","author":"S Salama","year":"2018","unstructured":"Salama, S. et al. Clinical and radiological characteristics of neuromyelitis optica spectrum disorder in the North Egyptian Nile Delta. J. Neuroimmunol. 324, 22\u201325. https:\/\/doi.org\/10.1016\/j.jneuroim.2018.08.014 (2018).","journal-title":"J. Neuroimmunol."},{"issue":"10","key":"83760_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neurol.2018.01.378","volume":"174","author":"A Ungureanu","year":"2018","unstructured":"Ungureanu, A., de Seze, J., Ahle, G. & Sellal, F. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. Rev. Neurol. (Paris) 174(10), 675\u2013679. https:\/\/doi.org\/10.1016\/j.neurol.2018.01.378 (2018).","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"83760_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pathophys.2010.04.008","volume":"18","author":"J Kira","year":"2011","unstructured":"Kira, J. Neuromyelitis optica and opticospinal multiple sclerosis: Mechanisms and pathogenesis. Pathophysiology 18(1), 69\u201379. https:\/\/doi.org\/10.1016\/j.pathophys.2010.04.008 (2011).","journal-title":"Pathophysiology"},{"issue":"7","key":"83760_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock, S. J. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381(7), 614\u2013625. https:\/\/doi.org\/10.1056\/NEJMoa1900866 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"83760_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4103\/1673-5374.179048","volume":"11","author":"H Yokote","year":"2016","unstructured":"Yokote, H. & Mizusawa, H. Multiple sclerosis and neuromyelitis optica spectrum disorders: Some similarities in two distinct diseases. Neural Regen Res. 11(3), 410\u2013411. https:\/\/doi.org\/10.4103\/1673-5374.179048 (2016).","journal-title":"Neural Regen Res."},{"issue":"9","key":"83760_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J. & Weinshenker, B. G. The spectrum of neuromyelitis optica. Lancet Neurol. 6(9), 805\u2013815. https:\/\/doi.org\/10.1016\/S1474-4422(07)70216-8 (2007).","journal-title":"Lancet Neurol."},{"issue":"3","key":"83760_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley, J. et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol. 71(3), 276\u2013283. https:\/\/doi.org\/10.1001\/jamaneurol.2013.5857 (2014).","journal-title":"JAMA Neurol."},{"issue":"1","key":"83760_CR8","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","volume":"2","author":"M Reindl","year":"2015","unstructured":"Reindl, M. & Rostasy, K. MOG antibody-associated diseases. Neurol. Neuroimmunol. Neuroinflamm. 2(1), e60. https:\/\/doi.org\/10.1212\/NXI.0000000000000060 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"83760_CR9","doi-asserted-by":"publisher","unstructured":"Marignier, R. et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 20 (9), 762\u2013772. (2021) https:\/\/doi.org\/10.1016\/S1474-4422(21)00218-0. Erratum in: Lancet Neurol. 20 (10), e6. (2021) https:\/\/doi.org\/10.1016\/S1474-4422(21)00290-8. Erratum in: Lancet Neurol. 21 (1), e1. (2022) https:\/\/doi.org\/10.1016\/S1474-4422(21)00433-6.","DOI":"10.1016\/S1474-4422(21)00218-0 10.1016\/S1474-4422(21)00290-8 10.1016\/S1474-4422(21)00433-6"},{"issue":"4","key":"83760_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan, S., Dale, R. C. & Brilot, F. Anti-MOG antibody: The history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun. Rev. 15(4), 307\u2013324. https:\/\/doi.org\/10.1016\/j.autrev.2015.12.004 (2016).","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"83760_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell, B. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 22(3), 268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8 (2023).","journal-title":"Lancet Neurol."},{"issue":"8","key":"83760_CR12","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1007\/s00415-023-11737-8","volume":"270","author":"A Al-Ani","year":"2023","unstructured":"Al-Ani, A., Chen, J. J. & Costello, F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Current understanding and challenges. J. Neurol. 270(8), 4132\u20134150. https:\/\/doi.org\/10.1007\/s00415-023-11737-8 (2023).","journal-title":"J. Neurol."},{"issue":"4","key":"83760_CR13","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2214\/AJR.20.24061","volume":"216","author":"M Shahriari","year":"2021","unstructured":"Shahriari, M., Sotirchos, E. S., Newsome, S. D. & Yousem, D. M. MOGAD: How it differs from and resembles other neuroinflammatory disorders. AJR Am. J. Roentgenol. 216(4), 1031\u20131039. https:\/\/doi.org\/10.2214\/AJR.20.24061 (2021).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"83760_CR14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.4103\/1673-5374.385293","volume":"19","author":"T Akaishi","year":"2024","unstructured":"Akaishi, T. & Misu, T. Anti-aquaporin-4 antibody (AQP4-IgG) and anti-myelin oligodendrocyte glycoprotein antibody (MOG-IgG) in the cerebrospinal fluid. Neural Regen Res. 19(5), 949\u2013950. https:\/\/doi.org\/10.4103\/1673-5374.385293 (2024).","journal-title":"Neural Regen Res."},{"issue":"2","key":"83760_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2), 177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729 (2015).","journal-title":"Neurology"},{"issue":"11","key":"83760_CR16","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/wnl.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke, J. F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33(11), 1444\u20131452. https:\/\/doi.org\/10.1212\/wnl.33.11.1444 (1983).","journal-title":"Neurology"},{"issue":"6","key":"83760_CR17","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1055\/s-0039-3399505","volume":"39","author":"S Prasad","year":"2019","unstructured":"Prasad, S. & Chen, J. What you need to know about AQP4, MOG, and NMOSD. Semin. Neurol. 39(6), 718\u2013731. https:\/\/doi.org\/10.1055\/s-0039-3399505 (2019).","journal-title":"Semin. Neurol."},{"issue":"1","key":"83760_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12883-021-02171-2","volume":"21","author":"JL Hsu","year":"2021","unstructured":"Hsu, J. L., Liao, M. F., Chang, K. H., Cheng, M. Y. & Ro, L. S. Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD. BMC Neurol. 21(1), 153. https:\/\/doi.org\/10.1186\/s12883-021-02171-2 (2021).","journal-title":"BMC Neurol."},{"issue":"2","key":"83760_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/biomedicines7020042","volume":"7","author":"MA Lana-Peixoto","year":"2019","unstructured":"Lana-Peixoto, M. A. & Talim, N. Neuromyelitis optica spectrum disorder and Anti-MOG syndromes. Biomedicines 7(2), 42. https:\/\/doi.org\/10.3390\/biomedicines7020042 (2019).","journal-title":"Biomedicines"},{"issue":"381","key":"83760_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jns.2017.08.3254","volume":"15","author":"M Bouzar","year":"2017","unstructured":"Bouzar, M. et al. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. J. Neurol. Sci. 15(381), 240\u2013244. https:\/\/doi.org\/10.1016\/j.jns.2017.08.3254 (2017).","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"83760_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fneur.2020.00089","volume":"26","author":"F Alshamrani","year":"2020","unstructured":"Alshamrani, F., Alnajashi, H., Shosha, E., Casserly, C. & Morrow, S. A. Case series: Myelin oligodendrocyte glycoprotein-immunoglobulin G-related disease spectrum. Front. Neurol. 26(11), 89. https:\/\/doi.org\/10.3389\/fneur.2020.00089 (2020).","journal-title":"Front. Neurol."},{"issue":"6","key":"83760_CR22","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato, D. K. et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6), 474\u2013481. https:\/\/doi.org\/10.1212\/WNL.0000000000000101 (2014).","journal-title":"Neurology"},{"issue":"4","key":"83760_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000040","volume":"1","author":"S Ramanathan","year":"2014","unstructured":"Ramanathan, S. et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol. Neuroimmunol. Neuroinflamm. 1(4), e40. https:\/\/doi.org\/10.1212\/NXI.0000000000000040 (2014).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"12","key":"83760_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","volume":"8","author":"AK Pr\u00f6bstel","year":"2015","unstructured":"Pr\u00f6bstel, A. K. et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J. Neuroinflamm. 8(12), 46. https:\/\/doi.org\/10.1186\/s12974-015-0256-1 (2015).","journal-title":"J. Neuroinflamm."},{"issue":"12","key":"83760_CR25","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s11427-015-4997-y","volume":"59","author":"Y Yan","year":"2016","unstructured":"Yan, Y. et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci. China Life Sci. 59(12), 1270\u20131281. https:\/\/doi.org\/10.1007\/s11427-015-4997-y (2016).","journal-title":"Sci. China Life Sci."},{"issue":"11","key":"83760_CR26","doi-asserted-by":"publisher","first-page":"612304","DOI":"10.3389\/fneur.2020.612304","volume":"21","author":"L Brill","year":"2021","unstructured":"Brill, L. et al. Age-related clinical presentation of MOG-IgG seropositivity in Israel. Front. Neurol. 21(11), 612304. https:\/\/doi.org\/10.3389\/fneur.2020.612304 (2021).","journal-title":"Front. Neurol."},{"issue":"1","key":"83760_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo, A. et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann. Neurol. 89(1), 30\u201341. https:\/\/doi.org\/10.1002\/ana.25909 (2021).","journal-title":"Ann. Neurol."},{"key":"83760_CR28","doi-asserted-by":"publisher","first-page":"102773","DOI":"10.1016\/j.msard.2021.102773","volume":"49","author":"S Messina","year":"2021","unstructured":"Messina, S. et al. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive neuromyelitis optica spectrum disorder, MOG-Ab disease and multiple sclerosis. Mult. Scler. Relat. Disord. 49, 102773. https:\/\/doi.org\/10.1016\/j.msard.2021.102773 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"10","key":"83760_CR29","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","volume":"20","author":"A Uzawa","year":"2024","unstructured":"Uzawa, A., Oertel, F. C., Mori, M., Paul, F. & Kuwabara, S. NMOSD and MOGAD: An evolving disease spectrum. Nat. Rev. Neurol. 20(10), 602\u2013619. https:\/\/doi.org\/10.1038\/s41582-024-01014-1 (2024).","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"83760_CR30","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458515622986","volume":"22","author":"S Jarius","year":"2016","unstructured":"Jarius, S. et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in \u201cpattern II multiple sclerosis\u201d and brain biopsy findings in a MOG-IgG-positive case. Mult. Scler. 22(12), 1541\u20131549. https:\/\/doi.org\/10.1177\/1352458515622986 (2016).","journal-title":"Mult. Scler."},{"issue":"6","key":"83760_CR31","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1007\/s00415-021-10914-x","volume":"269","author":"T Akaishi","year":"2022","unstructured":"Akaishi, T. et al. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease. J. Neurol. 269(6), 3136\u20133146. https:\/\/doi.org\/10.1007\/s00415-021-10914-x (2022).","journal-title":"J. Neurol."},{"key":"83760_CR32","doi-asserted-by":"publisher","unstructured":"Jurynczyk, M. et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain. 140 (12), 3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276 (2017). Erratum in: Brain. 141 (4), e31. https:\/\/doi.org\/10.1093\/brain\/awy014 (2018).","DOI":"10.1093\/brain\/awx276 10.1093\/brain\/awy014"},{"issue":"2","key":"83760_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ana.25291","volume":"84","author":"M Spadaro","year":"2018","unstructured":"Spadaro, M. et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein. Ann. Neurol. 84(2), 315\u2013328. https:\/\/doi.org\/10.1002\/ana.25291 (2018).","journal-title":"Ann. Neurol."},{"key":"83760_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","volume":"25","author":"R Narayan","year":"2018","unstructured":"Narayan, R. et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult. Scler. Relat. Disord. 25, 66\u201372. https:\/\/doi.org\/10.1016\/j.msard.2018.07.025 (2018).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"83760_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055392","volume":"11","author":"S Huda","year":"2021","unstructured":"Huda, S. et al. Predictors of relapse in MOG antibody associated disease: A cohort study. BMJ Open. 11(11), e055392. https:\/\/doi.org\/10.1136\/bmjopen-2021-055392 (2021).","journal-title":"BMJ Open."},{"issue":"12","key":"83760_CR36","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","volume":"267","author":"DH Whittam","year":"2020","unstructured":"Whittam, D. H. et al. Treatment of MOG antibody associated disorders: Results of an international survey. J. Neurol. 267(12), 3565\u20133577. https:\/\/doi.org\/10.1007\/s00415-020-10026-y (2020).","journal-title":"J. Neurol."},{"issue":"2","key":"83760_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/14728214.2021.1919082","volume":"26","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti, E., Marrodan, M. & Correale, J. Emerging drugs for the treatment of adult MOG-IgG-associated diseases. Expert Opin. Emerg. Drugs 26(2), 75\u201378. https:\/\/doi.org\/10.1080\/14728214.2021.1919082 (2021).","journal-title":"Expert Opin. Emerg. Drugs"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83760-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83760-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T05:06:15Z","timestamp":1736399175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83760-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83760"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83760-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted following the ethical guidelines for research defined in the Declaration of Helsinki. This study was carried out after the approval of the ethical committee of Ain Shams University, Faculty of Medicine (FMASU MS176\/2019). Before participating in this study, all subjects or their primary relatives conferred a written informed consent form. All collected data were kept private and confidential and were solely utilized for the study\u2019s purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"1438"}}